Why GLP-1 Doses Change Over Time

Titration means adjusting a medication dose over time according to an established prescribing plan and the patient’s clinical response. FDA-approved semaglutide and tirzepatide products used for weight management include stepwise dose-escalation instructions in their labeling. The exact schedule depends on the product, indication and individual clinical circumstances. This guide explains the concept, not a personal dosing schedule.

Gastrointestinal adverse effects are common with GLP-1 and related incretin medications. Approved labeling uses gradual dose escalation to reduce the likelihood or severity of gastrointestinal reactions and provides instructions for what to do when a dose is not tolerated. That is why “faster” is not automatically “better.” A dose that cannot be tolerated is not a useful shortcut.

Depending on the medication and indication, labeling may provide more than one maintenance dose or instructions based on response and tolerability. The clinically appropriate dose is not determined by internet comparisons or by what another patient is taking. Your prescriber should decide whether a dose changes, stays the same or requires another plan.

Before follow-up, think about your overall weight trend; appetite or eating changes; side effects and when they occur; nutrition and hydration; activity and strength; new medications or illnesses; and any questions about the prescription. Those details help the care team evaluate both response and tolerability — the two sides of a useful titration conversation.

A schedule for one FDA-approved product may not be the schedule for another product. A compounded prescription may also have formulation, concentration and measurement details that require product-specific directions. Do not convert, accelerate, skip ahead or copy a dose schedule without the prescribing clinician. If instructions are unclear, ask before using the medication.